Patrys Ltd represents values and a corporate philosophy centered around innovation, collaboration, and commitment to improving patients' lives. The company fosters a culture of scientific excellence, aiming to develop breakthrough antibody therapies for cancer treatment. Patrys Ltd is driven by a patient-centric approach, striving to make a meaningful difference in cancer patients' outcomes through novel and targeted solutions. With a strong focus on research and development, Patrys Ltd is dedicated to advancing the field of oncology and delivering innovative therapies to address unmet medical needs. This commitment underscores Patrys Ltd's passion for improving the lives of cancer patients worldwide.

Patrys Ltd is primarily present in Australia.

Patrys Ltd has achieved several significant milestones in its history. Firstly, the company successfully completed its initial public offering (IPO) and got listed on the stock exchange, which allowed it to raise capital for growth and expansion. Additionally, Patrys Ltd has made remarkable breakthroughs in its research and development activities, leading to the development of innovative and potentially impactful therapies. This includes the advancement of its lead drug candidate, PAT-DX1, which has shown promising results in preclinical studies. Furthermore, Patrys Ltd has established strategic collaborations with renowned research institutions and pharmaceutical companies, further validating its scientific expertise and creating potential opportunities for future success.

Patrys Ltd is a biotechnology company founded in 2006 and headquartered in Melbourne, Australia. The company focuses on the development of novel antibodies for the treatment of cancer. Patrys Ltd has a strong research and development pipeline, aiming to create innovative and targeted therapies to address unmet medical needs in oncology. With a diverse portfolio of intellectual property, Patrys Ltd has achieved significant milestones and collaborations with leading industry partners. The company is dedicated to advancing its cutting-edge technologies and bringing new and effective cancer treatments to patients worldwide.

The main competitors of Patrys Ltd in the market include other companies operating in the biotechnology and pharmaceutical industries. These competitors may include well-established firms with a similar focus on developing innovative therapies and drugs. However, it is essential to conduct thorough market research to determine the specific competitors relevant to Patrys Ltd's offerings and target market. Stay updated with Patrys Ltd's latest announcements and industry news to gather accurate information about its current competitors.

Patrys Ltd is primarily active in the biotechnology industry.

The business model of Patrys Ltd is focused on developing and commercializing innovative cancer therapies. Patrys is a biotechnology company that specializes in the development of antibodies for the treatment of cancer and other diseases. The company's key focus is on advancing its proprietary platform technology, PAT-SMART™, which aims to create novel therapies targeting a range of cancers. Patrys collaborates with leading research institutions and experts to develop and test its drug candidates. Through its business model centered around research and development, Patrys aims to bring novel therapies to market that have the potential to improve patient outcomes in the field of oncology.

Patrys P/E-luku on −2,32.

Patrys KUV on 5,90.

AlleAktien Laatuscore Patrys on 2/10.

Patrys liikevaihto on 1,39 milj. AUD.

Patrys voitto on −3,54 milj. AUD.

Patrys Ltd is a biopharmaceutical company specializing in the discovery, development, and commercialization of antibodies against cancer and other diseases. Founded in 2000, the company is headquartered in Australia and has offices in the USA and Europe. Patrys' business model includes multiple divisions focused on product development and commercialization in various areas. The first division of Patrys focuses on the research and development of antibodies against cancer. The company utilizes its patented technologies to discover novel antibodies specifically targeting cancer cells. These discoveries are then further developed to assess safety and efficacy in clinical trials, with the goal of bringing them to market as new treatment options. Another division of Patrys is the manufacturing and commercialization of antibodies against autoimmune diseases such as Multiple Sclerosis (MS) and rheumatoid arthritis (RA). Patrys' developments in this area aim to identify specific antibodies that inhibit autoimmune reactions without suppressing the immune system overall. The company works closely with leading academics and clinicians to evaluate the efficacy of the developed antibodies and collect extensive clinical data. Thirdly, Patrys has a division for the development of therapeutic antibodies against infectious diseases such as Hepatitis B and C, as well as HIV. The company collaborates closely with scientists and experts in this field to develop antibodies that can directly bind to specific viral proteins and inhibit their spread. In addition to these main divisions, Patrys is also involved in licensing its technologies and know-how to other companies and research institutions. The company has an extensive patent portfolio relating to the discovery of cancer-targeting antibodies and immune-regulatory proteins. These patents are valuable to other biopharmaceutical companies and research institutions pursuing similar developments. Patrys also produces a range of diagnostic products used for the detection and monitoring of cancer and autoimmune diseases. These tests are developed and marketed in collaboration with other companies and institutions. Overall, Patrys' business model is focused on the discovery and development of novel antibodies and biological therapeutics against cancer, autoimmune diseases, and infectious diseases. These developments are valuable both for clinical practice and for licensing to other companies. Patrys aims to continuously expand and optimize its portfolio of diagnostics and therapeutics in collaboration with leading scientists and clinicians.

Patrys maksaa osinkoa 0 AUD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Patrys:lle tai yhtiö ei maksa osinkoa.

Patrys:n ISIN on AU000000PAB9.

Patrys:n WKN on A0MU4Y.

Patrys:n tunnus on PAB.AX.

Viimeisen 12 kuukauden aikana Patrys maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Patrys maksanee ennusteiden mukaan 0 AUD osingon.

Patrys:n tämänhetkinen osinkotuotto on .

Patrys maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Patrys maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 AUD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Patrys kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Patrys osingon 10.11.2024, jonka suuruus on 0 AUD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 10.11.2024.

Viimeisin osinko maksettiin 10.11.2024.

Vuonna 2023 Patrys maksoi 0 AUD osinkoina.

Patrys:n osingot maksetaan AUDssa.